Biochemical fingerprints reveal diabetes progression
Researchers have described a new method to study biochemical changes that occur in the pancreas during the development of diabetes...
List view / Grid view
Researchers have described a new method to study biochemical changes that occur in the pancreas during the development of diabetes...
Researchers have developed a method that could make magnetic resonance imaging (MRI) multicoloured - a strategy that could serve as a research tool and even aid disease diagnosis...
Oramed announced today the appointment of Dr Simon Bruce MD to the newly created position of Vice President of Medical Affairs...
European Pharmaceutical Review, Issue 2 of 2016 focused on nanotechnology and stem cell technology to monitor glucose and prevent diabetes, respectively. The aim of this review is to sensitise the technology innovators in this field by providing expert opinions on biomedical products and technologies that have come the closest so…
Over the last decade, research has revealed more about the human gut microbiome—the environment within the gastrointestinal tract—where microbes, especially bacteria, reside.
More work needs to be done to examine the real world effects of the commonly prescribed diabetes drug empagliflozin, new research finds...
In the first large pragmatic trial of its kind in the United States, results from a study show that checking finger-stick blood sugars may not help diabetes patients who do not use insulin.
19 April 2017 | By Niamh Marriott, Junior Editor
GeNeuro have started a Phase 2a clinical study in Australia with GNbAC1 in patients with Type 1 diabetes. GNbAC1 is a monoclonal antibody designed to...
The annual Drugs to Watch report forecasts that eight new drugs will enter the market in 2017 and achieve blockbuster sales of more than $900 billion by 2021...
3 April 2017 | By Dr David Pugh, IDTechEx
The latest 2017 pipelines explores new emerging methods of glucose monitoring, analysing these technologies in the new report from IDTechEx Research...
19 January 2017 | By Niamh Marriott, Digital Editor
Suliqua is an innovative new combination therapy that has the potential to address significant unmet needs for people living with type 2 diabetes in Europe
5 January 2017 | By Niamh Marriott, Digital Editor
In the trial, empagliflozin significantly reduced the relative risk of the combined primary endpoint of cardiovascular death, non-fatal heart attack by 14%...
4 January 2017 | By Niamh Louise Marriott, Digital Editor
It is indicated for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin (less than 60 Units daily) or lixisenatide...
29 November 2016 | By Niamh Louise Marriott, Digital Editor
Soliqua 100/33 is the combination of Lantus (insulin glargine 100 Units/mL) and lixisenatide, a GLP-1 receptor agonist, studied in a Phase 3 program...
4 November 2016 | By Niamh Louise Marriott, Digital Content Producer
New data from a study related to post-meal or postprandial glucose control, show that poor PPG control has a negative impact on diabetics quality of life...